Compare Tango Therapeutics Inc. (TNGX) vs White Mountains Insurance Group Ltd. Common Stock (WTM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs White Mountains Insurance Group Ltd. Common Stock — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while White Mountains Insurance Group Ltd. Common Stock trades at $2,096.01 (market cap $5.00B). The key difference: White Mountains Insurance Group Ltd. Common Stock is the larger of the two by market cap, and White Mountains Insurance Group Ltd. Common Stock pays a 0.05% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals.
| TNGX | WTM | |
|---|---|---|
Market Cap | $3.75B | $5.00B |
Volume | 9,619,106 | 16,109 |
Sector | Health | Financials |
52-Week High | $32.90 | $2.32K |
52-Week Low | $7.50 | $1.85K |
Typical Hold Time | 0 Days | — |
Enterprise Value | $2.77B | $5.83B |
Dividend Yield | — | 0.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
White Mountains Insurance Group (WTM) trades at $2,093.13, up 0.31% with neutral technical signals. The stock shows strong fundamentals with a P/E of 4.8 and ROE of 21.9%, though recent earnings were mixed with Q2 2026 beating estimates while Q1 missed. Book value per share reached $2,258 as of June 2026, up 4% quarterly. Recent product launches and board additions signal strategic growth initiatives.
WTM presents value investment appeal with attractive valuation multiples and solid profitability, but faces execution risks from volatile quarterly earnings and negative cash flow trends. Analyst consensus remains neutral with 100% hold ratings, suggesting cautious optimism pending clearer earnings consistency and cash flow improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About White Mountains Insurance Group Ltd. Common Stock
White Mountains Insurance Group Ltd. is a Bermuda-based holding company that owns and builds insurance and financial services businesses. Its operating segments include Ark, a specialty insurance and reinsurance underwriter; HG Global, which reinsures municipal bond insurer Build America Mutual; and Kudu Investment Management, which provides capital to boutique asset managers.
Read more on WTM →
